{"organizations": [], "uuid": "8354077a4aa510e33808e1aa16a33d52b98cf679", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-santhera-pharmaceuticals-holding-2/brief-santhera-pharmaceuticals-holding-2017-revenues-from-sales-of-raxone-up-at-chf-22-9-million-idUSFWN1PN01U", "country": "US", "domain_rank": 408, "title": "BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-29T14:06:00.000+02:00", "replies_count": 0, "uuid": "8354077a4aa510e33808e1aa16a33d52b98cf679"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-santhera-pharmaceuticals-holding-2/brief-santhera-pharmaceuticals-holding-2017-revenues-from-sales-of-raxone-up-at-chf-22-9-million-idUSFWN1PN01U", "ord_in_thread": 0, "title": "BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million", "locations": [], "entities": {"persons": [], "locations": [{"name": "santhera", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pharmaceuticals holding ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 29 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :\n* INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE\n* FOR 2017, SANTHERA ANTICIPATES A NET RESULT OF CHF -50 TO -55 MILLION.\n* FOR 2018 EXPECTS NET SALES OF RAXONE FOR CURRENTLY APPROVED INDICATION LHON TO REACH CHF 28 TO 30 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-29T14:06:00.000+02:00", "crawled": "2018-01-30T19:11:06.000+02:00", "highlightTitle": ""}